Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 20;25(4):278-286.
doi: 10.3779/j.issn.1009-3419.2022.101.16.

[Anti-angiogenesis in Lung Cancer: Current Situation, Progress and Confusion]

[Article in Chinese]
Zhou Jiang  1 , Jianhua Chen  1
Affiliations
Review

[Anti-angiogenesis in Lung Cancer: Current Situation, Progress and Confusion]

[Article in Chinese]
Zhou Jiang et al. Zhongguo Fei Ai Za Zhi. .

Abstract
in English, Chinese

Lung cancer is a highly vascular tumors, over the past ten years, anti-angiogenes is has been proved to be an effective and highly promising combinational treatment. The data of the combination of anti-angiogenesis with chemotherapy, targeted therapy, immunotherapy has been constantly updating. Advanced lung cancer patients, no matter different groups or different stages of the disease, are benefited from anti-angiogenes. In this paper, based on the clinical status and unsolved problems, combined with the latest clinical and translational research data, we reviewed the current anti-angiogenesis treatment of lung cancer. .

【中文题目：肺癌抗血管生成治疗：现状、进展与困惑】 【中文摘要：肺癌是一种高度血管化的肿瘤，过去十多年，抑制血管生成已被证实是一种有效且极具前景的联合治疗选择，关于抗血管生成治疗与化疗、靶向治疗、免疫治疗的联合疗效数据在不断更新，其在晚期肺癌不同群体以及疾病的不同阶段均可带来获益，伴随而来的是对众多治疗策略的“排列组合”及“排兵布阵”的困惑，本文将基于临床现状及尚未解决的问题，结合最新临床及转化研究数据，对当前肺癌抗血管生成治疗作一综述。 】 【中文关键词：肺肿瘤；抗血管生成；联合治疗；新策略】.

Keywords: Anti-angiogenesis; Combination therapy; Lung neoplasms; New strategy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58–62. doi: 10.1126/science.1104819. - DOI - PubMed
    1. Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol. 2021;16(2):205–215. doi: 10.1016/j.jtho.2020.10.006. - DOI - PubMed
    1. Yi M, Jiao D, Qin S, et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60. doi: 10.1186/s12943-019-0974-6. - DOI - PMC - PubMed
    1. Goveia J, Rohlenova K, Taverna F, et al. An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates. Cancer Cell. 2020;37(1):21–36.e13. doi: 10.1016/j.ccell.2019.12.001. - DOI - PubMed
    1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–2550. doi: 10.1056/NEJMoa061884. - DOI - PubMed

MeSH terms

Substances